Stories about Central nervous system

Subscribe to topic

Subscribe to Central nervous system

10.12.2019 – 01:45
UCB Pharma
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
more
10.10.2019 – 09:38
UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Brussels and Cambridge, Massachusetts (ots/PRNewswire) - - Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - ...
more
24.06.2019 – 14:00
Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
more
24.06.2019 – 11:35
Gedeon Richter Pharma GmbH
Experts Discuss: 'Social Egg Freezing' - Does It Alleviate or Increase the Pressure Among Women to Have a Baby Early?
Vienna (ots/PRNewswire) - A panel of leading fertility experts discuss fertility preservation considerations for women on their fertility journey Experts have gathered at a Gedeon Richter-sponsored panel discussion to debate the pressure paradox of egg freezing, a procedure which is on the rise in Europe.1 In the ...
more
30.05.2019 – 10:01
Merck KGaA
Merck Pioneers New Efforts to See MS From the Inside Out
Darmstadt, Germany (ots/PRNewswire) - Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate ...
more
30.04.2019 – 14:05
Merck KGaA
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Merck, a leading science and technology company, today announced that data from ...
more
30.03.2019 – 01:02
Merck KGaA
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy ...
more
25.03.2019 – 12:04
Merck KGaA
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
more
03.01.2019 – 08:01
NORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...
more
18.10.2018 – 07:01
UCB Pharma
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase
Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...
more
11.10.2018 – 19:31
Merck KGaA
Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S media - Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those impacted by MS Merck, a leading science and ...
more
09.10.2018 – 10:15
Helmholtz Zentrum München
Satiety in 3D
Many overweight people lack the feeling of being full. It was long thought that this was due to the disrupted transport of the satiety hormone leptin to the brain. That is not the case, as a group of scientists from Helmholtz Zentrum München has now shown in the 'International Journal of Obesity'. The work was made possible by a new 3D imaging technique that allows tracking the path of the hormone in the brain as shown in the video image enclosed. Leptin is an important ...
more
14.07.2015 – 18:48
Zambon GmbH
Zambon Expands in Europe Acquiring Nigaard
Milan (ots/PRNewswire) - The deal will speed up the commercialization of Xadago(R) for the treatment of Parkinson's Disease Nigaard is a pharmaceutical company well established in Denmark, Norway, Sweden, Iceland and Finland Zambon S.p.A., an international pharmaceutical company strongly committed to the Central Nervous System (CNS) therapeutic area and the Respiratory area with a focus on Rare Diseases, announced today ...
more

1